Suppr超能文献

对于伴有N2-3期淋巴结转移的局部晚期鼻咽癌患者,在同步放化疗基础上加用多西他赛、顺铂和5-氟尿嘧啶诱导化疗的生存获益情况。

Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.

作者信息

Kawahira Masahiro, Yokota Tomoya, Hamauchi Satoshi, Onozawa Yusuke, Ogawa Hirofumi, Onoe Tsuyoshi, Kamijo Tomoyuki, Iida Yoshiyuki, Nishimura Tetsuo, Onitsuka Tetsuro, Yasui Hirofumi

机构信息

Division of Gastrointestinal Oncology, Shizuoka.

Division of Medical Oncology, Shizuoka.

出版信息

Jpn J Clin Oncol. 2017 Aug 1;47(8):705-712. doi: 10.1093/jjco/hyx057.

Abstract

BACKGROUND

Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) has been established as the standard of care in locally advanced nasopharyngeal carcinoma (LA-NPC). The survival benefit of induction chemotherapy (ICT) for LA-NPC remains controversial. We analyzed the efficacy and feasibility of docetaxel, cisplatin and 5-fluorouracil (TPF) ICT followed by CCRT for LA-NPC with nodal Stage N2-3.

METHODS

We performed a retrospective analysis of 28 LA-NPC patients with nodal Stage N2-3 receiving induction TPF followed by CCRT (TPF group; n = 12) or CCRT-AC (CCRT group; n = 16) between October 2006 and May 2016.

RESULTS

The median follow-up periods were 36.4 (range 6.7-55.2) and 40.1 months (range 4.3-99.0) for the TPF and CCRT groups, respectively. One- and three-year overall survival for the TPF group vs. the CCRT group were 100% and 100% vs. 94% and 75%, respectively (P = 0.21). The cumulative one- and three-year incidences of locoregional recurrence or progression for the TPF group vs. the CCRT group were 10% and 21% vs. 16% and 32% (P = 0.49), and those of distant metastasis were 0% and 0% vs. 26% and 26%, respectively (P = 0.08). The common Grade 3-4 acute toxicities were neutropenia, anorexia, febrile neutropenia, and stomatitis in the TPF group. The Grade 3-4 late toxicities did not differ significantly between the two groups.

CONCLUSIONS

This study suggests that induction TPF followed by CCRT might reduce distant metastasis, so this combination may be feasible for the treatment of LA-NPC with nodal Stage N2-3.

摘要

背景

同步放化疗后序贯辅助化疗(CCRT-AC)已成为局部晚期鼻咽癌(LA-NPC)的标准治疗方案。诱导化疗(ICT)对LA-NPC的生存获益仍存在争议。我们分析了多西他赛、顺铂和5-氟尿嘧啶(TPF)诱导化疗后行CCRT治疗N2-3期LA-NPC的疗效和可行性。

方法

我们对2006年10月至2016年5月期间28例N2-3期LA-NPC患者进行回顾性分析,这些患者接受诱导TPF化疗后行CCRT(TPF组;n = 12)或CCRT-AC(CCRT组;n = 16)。

结果

TPF组和CCRT组的中位随访时间分别为36.4个月(范围6.7 - 55.2个月)和40.1个月(范围4.3 - 99.0个月)。TPF组与CCRT组的1年和3年总生存率分别为100%和100% vs. 94%和75%(P = 0.21)。TPF组与CCRT组局部区域复发或进展的1年和3年累积发生率分别为10%和21% vs. 16%和32%(P = 0.49),远处转移的累积发生率分别为0%和0% vs. 26%和26%(P = 0.08)。TPF组常见的3 - 4级急性毒性反应为中性粒细胞减少、厌食、发热性中性粒细胞减少和口腔炎。两组3 - 4级晚期毒性反应无显著差异。

结论

本研究表明,诱导TPF化疗后行CCRT可能减少远处转移,因此这种联合方案对于治疗N2-3期LA-NPC可能是可行的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验